Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roy Herbst MD, PhD

Roy S. Herbst MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center, New Haven, CT

Recent Contributions to PracticeUpdate:

  1. Health-Related Quality of Life Among Patients Treated With Immunotherapy Versus Chemotherapy for Lung Cancer
  2. Ramucirumab Plus Pembrolizumab for Lung Cancer
  3. Association Between Tumor Mutational Burden and Outcomes Among Patients Treated With Pembrolizumab for Lung Cancer
  4. Outcomes With Pembrolizumab Monotherapy Among Patients With PD-L1-Positive Lung Cancer and Brain Metastases
  5. Using Genomics in Lung Cancer: Practice Recommendations
  6. Upfront PD-1 Inhibitor Treatment for NSCLC: A New Paradigm
  7. ASCO 2017: Management of NSCLC Patients Pre-Treated With PD-1 Inhibitors
  8. New Evidence Review From ASCO in Lung Cancer: Recent Data on TKIs
  9. An Overview of Immunotherapy in Thoracic Cancer by Roy Herbst
  10. Predictors of Immunotherapy Response in Lung Cancer: Biomarkers, Mutational Load and Tumor Biology

Most Read This Week

Recently Updated